TNGX · Tango Therapeutics, Inc.
$26.65
-0.07 (-0.26%)
At close · Jul 28
Market Cap
$3.85B
Shares
144.65M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.65
Open$26.68
Day$25.33–26.94
52W$5.77–34.39
Avg vol 30d4.0M
Short int42.7M · 29.5% float · 15.3d
Short vol51%
DataSep 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+56%
above
Price vs 50-day avg
−1%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
73%
mid-range
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+123%
trailing
YTD return
+201%
this year
Relative strength
+116%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
25 of 194 funds reported for Jun 30 · net +887.8K sh shares · +8 new
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
29.53% of float · ▲ +1.7% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
194 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+48%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-139.9M
Balance sheet
$112.3M
net cash
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+56%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
73%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $27 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
25 of 194 funds reported for Jun 30 · net +887.8K sh shares · +8 new
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
29.53% of float · ▲ +1.7% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
194 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $27 · 73%
52-wk high $34
vs 200-day avg +56%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNGX
this stock
Tango Therapeutics, Inc.
|
$3.85B | +200.8% | +46.9% | — | 29.5% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNGX | -3.2% | -15.3% | +123.2% | -14.8% | +200.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -2.2% | -15.3% | +115.8% | -14.0% | +192.2% |
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
24 filings
24 filers
Visit website
Investor relations